February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

cardiovascular diseases, renal diseases, autoimmune diseases such as systemic sclerosis or systemic lupus

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Aelis

gene therapies for sickle cell disease, including first that uses CRISPR Pier Vincenzo Piazza, CEO of AELIS

Exscientia plc in deal worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis

presenting at the OBIO 2024 Investment Summit X-rays to AlphaFold: the future structure of drug discovery Aelis

Industry News Addex Therapeutics Reports Full Year 2023 Financial Results And Provides Corporate Update Aelis

Cellular Communication Bowes Biomedical Investigator Takes Aim at Cracking Cellular Communication Code Aelis

for the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus